# Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform

- Link: https://www.thailand-business-news.com/pr-news/creative-life-science-advances-pic-s-gmp-compliant-cell-therapy-materials-and-manufacturing-platform
- Published: 2026-07-17T13:12:00+07:00
- Author: PR Newswire

**Targets Japan and Singapore as Part of Broader Asia Expansion**

TAIPEI, July 17, 2026 /PRNewswire/ — BIO Asia-Taiwan 2026 opens July 16 at the Taipei
Nangang Exhibition Center and runs through July 19. Creative Life Science (7837)
is showcasing its upstream regenerative medicine materials, process-development 
capabilities and quality-testing services, highlighting the build-out and service
capacity of its Zhubei biomanufacturing facility.

Creative Life Science reported cumulative revenue of NT$568 million for the first
half of 2026, up 13.18% year on year and a record high for the period. Building 
on its established portfolio of culture media, diagnostic reagents and testing services,
the company has identified critical regenerative medicine materials, process services
and international partnerships as key growth drivers.

[⌊Creative Life Science showcased its Zhubei biomedical facility at 2026 BIO Asia-
Taiwan, highlighting its Taiwan-based manufacturing and quality systems as it advances
critical raw materials for regenerative medicine and expands across Asian markets.⌉⌊
Creative Life Science showcased its Zhubei biomedical facility at 2026 BIO Asia-
Taiwan, highlighting its Taiwan-based manufacturing and quality systems as it advances
critical raw materials for regenerative medicine and expands across Asian markets
.⌉[
Creative Life Science showcased its Zhubei biomedical facility at 2026 BIO Asia-
Taiwan, highlighting its Taiwan-based manufacturing and quality systems as it advances
critical raw materials for regenerative medicine and expands across Asian markets.

As cell and gene therapies move from clinical translation toward commercialization,
Taiwan’s two landmark regenerative medicine laws and related implementing regulations—
introduced progressively from 2025 and fully effective as of Jan. 1, 2026 — are 
raising the bar for material traceability, process scale-up, aseptic manufacturing,
batch release and analytical testing. These capabilities have become critical gateways
to clinical development and market entry. Creative Life Science supports the upstream
regenerative medicine ecosystem with GMP-grade culture media, serum-free media, 
cryopreservation solutions, cell-process development, aseptic filling and quality-
control testing.

Located in the Hsinchu Biomedical Science Park, the company’s 2,180-square-meter
Zhubei facility is PIC/S GMP-compliant. It incorporates ISO Class 5 isolators and
automated aseptic filling systems, together with a quality management framework 
aligned with QMS/ISO 13485 principles and laboratory capabilities built around ISO/
IEC 17025. Services include process development and scale-up, research-use-only (
RUO)-to-GMP conversion, technology transfer, aseptic filling and quality testing,
helping customers accelerate the transition from R&D to clinical application.

In conjunction with the international engagement generated by BIO Asia-Taiwan, Creative
Life Science hosted the "2026 Taiwan Biotechnology Industry Delegation" on July 
14. Organized by Taiwan’s Overseas Community Affairs Council, the delegation brought
together 21 overseas Taiwanese entrepreneurs and business leaders from 10 countries
across four continents. Participants toured the cell culture media production line
and product showcase areas to gain first-hand insight into the company’s capabilities
in critical regenerative medicine materials, cell culture, process development and
quality testing.

Delegation members represented global pharmaceutical companies, contract development
and manufacturing organizations (CDMOs), genetic engineering and life sciences investment.
Participants included a CMC product development executive from Alnylam, a global
leader in RNA interference therapeutics, and a global regulatory affairs director
from AstraZeneca.

In late 2025, Creative Life Science signed a cooperation agreement with Singapore-
based ESCO, establishing a foundation for collaboration in Southeast Asia. The company
plans to continue expanding its presence in Singapore, Japan and other Asian markets.
During BIO Asia-Taiwan, it will host the seminar "From Standardization to Product
Release: Critical Analytical Strategies for Regenerative Medicine Product Development"
on July 17, covering process development, analytical methods and product-release
practices.

**About Creative Life Science**

Creative Life Science has built longstanding expertise in microbiological culture
media, diagnostic reagents, quality testing and biopharmaceutical services. In recent
years, the company has expanded into the upstream supply chain for regenerative 
medicine and cell therapy, with a focus on GMP-grade culture media manufacturing,
cell preservation solutions, process development and quality testing. Creative Life
Science is registered on Taiwan’s Emerging Stock Market and plans to apply for listing
on the Taipei Exchange in the second half of 2026.

**Exhibition Information**

 ◦ 2026 BIO Asia-Taiwan | Creative Life Science Booth M917, 4F, Taipei Nangang Exhibition
   Center, Hall 1
 ◦ Featured Seminar: From Standardization to Product Release: Critical Analytical
   Strategies for Regenerative Medicine Product Development
 ◦ July 17 | Room 507, Taipei Nangang Exhibition Center, Hall 1

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform ](http://www.prnasia.com/story/archive/5006172_AE06172_0?rand=184833)
